How Kisspeptin-10 works
A short-acting experimental peptide that triggers reproductive hormone release.
Also called: KP-10, KP10, Kisspeptin 112-121, Metastin 45-54, NSC 741805.
Reproductive axis peptides · KISS1 receptor agonist.
It switches on kisspeptin receptors on brain cells that release GnRH. GnRH tells the pituitary to release LH and FSH, which signal the testes or ovaries. The response depends on the person’s hormone levels and whether this pathway works.
- KISS1R / GPR54: Activates GnRH-releasing brain cells.
- GnRH → LH and FSH: Changes signals to the testes and ovaries; sex-hormone effects vary.
Half-life: IV plasma disappearance: 3.8 ± 0.3 minutes in men and 4.1 ± 0.4 minutes in women. This is not the duration of hormonal effects.
Related to Kisspeptin-10
- Gonadorelin: A short-acting fertility hormone used in tests and specialist pump therapy.
- hCG: A fertility hormone with limited testosterone add-on evidence and no proven weight-loss benefit.
- Bremelanotide: An as-needed injection for low libido before menopause; nausea is common.
- Hexarelin: A peptide that releases growth hormone; repeated use can weaken the response.
Sources
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Supply unlicensed medicinal products (specials), MHRA · 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee
- October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting
- Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks, Health Canada
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men., Yeung AC et al. · European journal of endocrinology · 2026
- Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men., Naveed A et al. · Hormones (Athens, Greece) · 2026
- Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans., Galbiati F et al. · Journal of neuroendocrinology · 2026
- Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans., Mills EG et al. · EBioMedicine · 2025
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.